Skip to main
  1. Stocks
  2. Twist Bioscience Corp
  3. Forecast
TWST

TWST Stock Forecast & Price Target

TWST Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 9%

Bulls say

Twist Bioscience is well positioned because its silicon-based DNA synthesis platform lowers cost and increases throughput, creating a structural advantage in a market where scale and speed are critical, while its expanding footprint across synthetic biology, AI drug discovery, and NGS broadens growth drivers. Management’s FY27 guidance for $550M-$560M of revenue, ~$52.5%-53.0% gross margin, and positive adjusted EBITDA suggests a path to profitable growth even as the company invests about $75M in FY27 CapEx to expand capacity, automation, and software. The positive outlook is further supported by $100M of FY27 AI revenue, 20%+ NGS growth, commercial MRD launch, and 16 DNA writers of capacity equivalent to 50M+ pieces of DNA per day, all indicating strong demand and operating leverage.

Bears say

Twist Bioscience is facing a more cautious fundamental setup because FY27 guidance reset expectations, with management signaling at least $100M of AI revenue as a floor while implying a deceleration in ex-AI DSPS, which raises concern that near-term growth may not keep pace with optimism. Although F4Q26 revenue, gross margins, and adjusted EBITDA profitability were achieved on schedule, the company still appears dependent on significant quarterly beats to prove AI demand is additive rather than offsetting weakness in the legacy business. Added risk comes from slower NGS end-market growth, a sluggish biopharma R&D recovery, and possible competitive pressure, all of which could limit the sustainability of the beat-and-raise narrative.

TWST has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.

TWST Analyst Forecast & Price Prediction

Get the latest TWST stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TWST

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Twist Bioscience Corp (TWST) Forecast

Analysts have given TWST a Buy based on their latest research and market trends.

According to 11 analysts, TWST has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $135.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $135.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Twist Bioscience Corp (TWST)


TWST Analyst Forecast & Price Prediction

Get the latest TWST stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TWST

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TWST stock data and trends